InVivo Biosystems
Eugene
About InVivo Biosystems
InVivo Biosystems is a biotechnology company that provides genome editing and in vivo analytical services to accelerate drug discovery and development. The company specializes in creating custom genome-edited C. elegans and zebrafish models to support research in neurological, metabolic, and rare monogenic diseases. Founded through the merger of NemaMetrix and Knudra Transgenics, InVivo Biosystems has developed proprietary technologies, including the RapidGen™ preclinical platform, to bridge the gap between cell culture and rodent models. This platform enables early-stage compound screening, toxicity testing, and efficacy analysis, providing biologically relevant data to inform critical decisions in the drug development process. The company serves pharmaceutical, nutraceutical, biotechnology companies, and academic research institutions, offering services such as CRISPR genome editing, zebrafish toxicity testing, and compound efficacy testing . InVivo Biosystems holds multiple global patents for its genome editing technologies and continues to innovate in the field of preclinical development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.8M
- Last round: Grant (Apr 2025)
- Website: invivobiosystems.com
- Phone: 844-663-8749
Industries & Categories
Biotechnology, Genetics, Life Science, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/invivo-biosystems-114551 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.